Publications by authors named "Jiangxue Hou"
Targeted Protein Degradation (TPD) represented by Proteolysis-Targeting Chimeras (PROTAC) is the frontier field in the research and development of antitumor therapy, in which oral drug HP518 Receives FDA Proceed Authorization for its IND Application for Prostate Cancer Treatment. Recently, molecular glue, functioning via degradation of the target protein is emerging as a promising modality for the development of therapeutic agents, while exhibits greater advantages over PROTAC, including improved efficiency, resistance-free properties, and the capacity to selectively target "undruggable" proteins. This marks a revolutionary advancement in the landscape of small molecule drugs.
View Article and Find Full Text PDFBispecific antibodies (BsAbs) and dual-targeted chimeric antigen receptor T (CAR T) cells have been employed in relapsed/refractory multiple myeloma (RRMM) patients over the past few years, as an increasing number of patients were ineffectively treated by ≥ 3 prior lines of therapy. BCMA/CD3 and GPRC5D/CD3 are the most popular combinations. Clinical findings indicated that patients exhibit a greater susceptibility to stronger and more enduring responses.
View Article and Find Full Text PDFBackground: Resembling acute promyelocytic leukemia (APL) is a unique subtype of APL who sharing clinical, morphological, and immunophenotypic features with typical APL, but lacking evidence of fusion gene and usually insensitive to arsenic trioxide (ATO) and all-trans retinoic acid (ATRA). For years, rearrangement were found in resembling APL continually. The confirmed partner genes of rearrangement included , , , , and .
View Article and Find Full Text PDF[NPM1 High Mutant Allele Burden is an Adverse Prognostic Factor for AML Patients with Mutated NPM1].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
April 2019
Article Synopsis
- - The study focused on 73 adult patients with acute myeloid leukemia (AML) who have mutated NPM1, examining their clinical features, gene mutations, and prognostic factors.
- - Researchers detected 74 mutations in the NPM1 gene and found that different mutation sites did not significantly affect patient prognosis, but a higher variant allele frequency (VAF) was linked to worse early mortality and survival rates.
- - The presence of NRAS mutations correlated with better outcomes, including higher remission rates and prolonged overall survival, and NPM1 VAF greater than 38.4% emerged as a key independent predictor of worse prognosis in these patients.